XML 35 R20.htm IDEA: XBRL DOCUMENT
v3.20.2

RELATED PARTY TRANSACTIONS | 9 Months Ended
--- | ---
Sep. 30, 2020
RELATED PARTY TRANSACTIONS |
RELATED PARTY TRANSACTIONS | NOTE 14: RELATED PARTY TRANSACTIONS The following table sets forth related party transaction expenses recorded for the three and nine months ended September 30, 2020 and 2019, respectively. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Three Months Ended |  | For the Nine Months Ended
​ | ​ | September 30, |  | September 30,
​ |  | 2020 |  | 2019 |  | 2020 |  | 2019
Research and development | ​ | $ | 405,000 | ​ | $ | 77,000 | ​ | $ | 864,000 | ​ | $ | 306,000
Total | ​ | $ | 405,000 |  | $ | 77,000 | ​ | $ | 864,000 |  | $ | 306,000
​ The detailed information for the table above is below. Sponsored Research Agreements with The Baylor College of Medicine (“BCM”). On November 16, 2018 and February 1, 2020, in furtherance of the BCM License Agreement and as contemplated by the terms thereof, the Company entered in Sponsored Research Agreements (“SRAs”) with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM’s Center for Cell and Gene Therapy. The following table sets forth related party transaction expenses recorded in connection with the SRAs for the three and nine months ended September 30, 2020 and 2019, respectively. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | For the Three Months Ended |  | For the Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ |  | 2020 |  | 2019 |  | 2020 |  | 2019
Research and development | ​ | $ | 11,000 | ​ | $ | 15,000 | ​ | $ | 68,000 | ​ | $ | 30,000
Total | ​ | $ | 11,000 | ​ | $ | 15,000 | ​ | $ | 68,000 | ​ | $ | 30,000
​ Clinical Supply Agreement with BCM. On September 9, 2019, in furtherance of the BCM License Agreement and as contemplated by the terms thereof, the Company entered in a Clinical Supply Agreement ("CSA") with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products. The following table sets forth related party transaction expenses recorded in connection with the CSA for the three and nine months ended September 30, 2020 and 2019, respectively. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | For the Three Months Ended |  | For the Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ |  | 2020 |  | 2019 |  | 2020 |  | 2019
Research and development | ​ | $ | — | ​ | $ | — | ​ | $ | 200,000 | ​ | $ | —
Total | ​ | $ | — | ​ | $ | — | ​ | $ | 200,000 | ​ | $ | —
​ Workforce Grant Agreement with BCM. On October 5, 2019, in furtherance of the BCM Clinical Supply Agreement and as contemplated by the terms thereof, the Company entered in a Workforce Grant Agreement ("WGA") with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities. The following table sets forth related party transaction expenses recorded in connection with the WGA for the three and nine months ended September 30, 2020 and 2019, respectively. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | For the Three Months Ended |  | For the Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ |  | 2020 |  | 2019 |  | 2020 |  | 2019
Research and development | ​ | $ | 130,000 | ​ | $ | — | ​ | $ | 278,000 | ​ | $ | —
Total | ​ | $ | 130,000 | ​ | $ | — | ​ | $ | 278,000 | ​ | $ | —
​ Clinical Trial Agreement with BCM. On August 17, 2020, in furtherance of the BCM Clinical Supply Agreement and as contemplated by the terms thereof, the Company entered in a Clinical Trial Agreement ("CTA") with BCM, which provided for BCM to provide to the Company investigator-initiated research studies. The following table sets forth related party transaction expenses recorded in connection with the CTA for the three and nine months ended September 30, 2020 and 2019, respectively. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Three Months Ended | ​ | For the Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ |  | 2020 |  | 2019 |  | 2020 |  | 2019
Research and development | ​ | $ | 213,000 | ​ | $ | — | ​ | $ | 213,000 | ​ | $ | —
Total | ​ | $ | 213,000 |  | $ | — | ​ | $ | 213,000 |  | $ | —
​ Purchases from Bio-Techne Corporation. The Company is currently utilizing Bio-Techne Corporation and two of its brands for the purchases of reagents, primarily cytokines. Mr. David Eansor is a member of the Company's board of directors and is serving as the President of the Protein Sciences Segment of Bio-Techne Corporation. The following table sets forth related party transaction expenses recorded in connection with Bio-Techne Corporation for the three and nine months ended September 30, 2020 and 2019, respectively. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | For the Three Months Ended |  | For the Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ |  | 2020 |  | 2019 |  | 2020 |  | 2019
Research and development | ​ | $ | 51,000 | ​ | $ | 4,000 | ​ | $ | 105,000 | ​ | $ | 43,000
Total | ​ | $ | 51,000 | ​ | $ | 4,000 | ​ | $ | 105,000 | ​ | $ | 43,000
​ Consulting Agreement with Dr. Juan Vera. On October 19, 2018, after the closing of the Company’s merger, the Company entered into a consulting agreement with Dr. Juan Vera, a member of the Company’s board of directors, to serve as the Company’s Chief Development Officer. On September 1, 2019, Dr. Vera became an employee of the Company and his consulting agreement was terminated. During the three and nine months ended September 30, 2019, the Company incurred approximately $58,000 and $233,000, respectively, of expenses under Dr. Vera’s consulting agreement. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Three Months Ended | ​ | For the Nine Months Ended
​ | ​ | September 30, | ​ | September 30,
​ |  | 2020 |  | 2019 |  | 2020 |  | 2019
Research and development | ​ | $ | — | ​ | $ | 58,000 | ​ | $ | — | ​ | $ | 233,000
Total | ​ | $ | — | ​ | $ | 58,000 |  | $ | — |  | $ | 233,000
​

X
- Definition Related Party Disclosure + References No definition available. + Details
Name: | mrkr_RelatedPartyDisclosureAbstract
Namespace Prefix: | mrkr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -URI http://asc.fasb.org/topic&trid=2122745 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864 + Details
Name: | us-gaap_RelatedPartyTransactionsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration